Guizhou Yibai Pharmaceuticals, which deals in R&D and sales of new drugs, was established on June 12, 1995, restructured as a joint-stock company, in November 2000, and went public on the Shanghai Stock Exchange (SHA: 600594), in March 2004, the first in Guizhou province.
It has world-class facilities and nine injection production lines and 49 types of drugs for small-volume injections, lyophilized powder injections, and infusions. Its major products include the Keke series and Aidi injections.
It covers a 134,398-square-meter space, with 43,200 sq m of it under national good manufacturing standards, and seven production bases, four of them outside Guizhou province. It had an output worth around 3 billion yuan ($489 million) and sales of about 2.8 billion yuan, by the end of 2012, and paid 386 million yuan in provincial taxes, and a total of 2.3 billion in State taxes since its founding.
In the first four month of 2013, Yibai has had 760 million yuan in production value and paid 135 million yuan in taxes, while sales increased 18 percent over the same last year period. Yibai has been on the Top 100 China Pharmaceutical Enterprise list for seven years in a row and was one of China's Top 20 Most Competitive Listed Pharmaceutical Companies, in 2012.
